{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:40:44Z","timestamp":1790797244396,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"abbvie inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40273-022-01132-y","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:02:35Z","timestamp":1647810155000},"page":"559-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson\u2019s Disease in England"],"prefix":"10.1007","volume":"40","author":[{"given":"K. Ray","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Simon","family":"Pickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash J.","family":"Jalundhwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Oddsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyavash","family":"Najle-Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Madin-Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"1132_CR1","unstructured":"Michael J Fox Foundation for Parkinson\u2019s Research. Parkinson's disease symptoms. https:\/\/www.michaeljfox.org\/understanding-parkinsons\/living-with-pd\/topic.php?symptoms&navid=symptoms. Accessed 3 Feb 2022."},{"issue":"3","key":"1132_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodrigurez-Blazquez C, Kurtis M, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord. 2011;26(3):399\u2013406.","journal-title":"Mov Disord."},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer RF. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016;22:S119\u201322.","journal-title":"Parkinsonism Relat Disord"},{"issue":"13","key":"1132_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583\u201390.","journal-title":"Mov Disord."},{"issue":"6","key":"1132_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol"},{"issue":"11","key":"1132_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson's Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol"},{"key":"1132_CR7","unstructured":"Parkinson's UK. The incidence and prevalence of Parkinson's in the United Kingdom. 2018. https:\/\/www.parkinsons.org.uk\/sites\/default\/files\/2018-01\/CS2960%20Incidence%20and%20prevalence%20report%20branding%20summary%20report.pdf. Accessed 3 Feb 2022."},{"issue":"2","key":"1132_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euroneuro.2010.08.002","volume":"21","author":"S von Campenhausen","year":"2011","unstructured":"von Campenhausen S, Winter Y, Silva A, et al. Costs of illness and care in Parkinson\u2019s disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21(2):180\u201391.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"10","key":"1132_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/mds.10507","volume":"8","author":"L Findley","year":"2003","unstructured":"Findley L, Aujla M, Bain P, et al. Direct economic impact of Parkinson\u2019s disease: a research survey in the United Kingdom. Mov Disord. 2003;8(10):1139\u201345.","journal-title":"Mov Disord."},{"issue":"10","key":"1132_CR10","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):e551\u201367.","journal-title":"Lancet Public Health."},{"issue":"6","key":"1132_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/mds.27302","volume":"33","author":"S Weir","year":"2018","unstructured":"Weir S, Samnaliev M, Kuo T, et al. Short- and long-term cost and utilization of health care resources in Parkinson\u2019s disease in the UK. Move Disord. 2018;33(6):974\u201381.","journal-title":"Move Disord."},{"issue":"1","key":"1132_CR12","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner C, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):17013.","journal-title":"Nat Rev Dis Primers"},{"key":"1132_CR13","unstructured":"NICE. Guideline, Parkinson\u2019s disease in adults (NG71). 2017. https:\/\/www.nice.org.uk\/guidance\/NG71. Accessed 3 Feb 2022."},{"issue":"8","key":"1132_CR14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim S, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Move Disord. 2018;33(8):1248\u201366.","journal-title":"Move Disord."},{"issue":"7","key":"1132_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","volume":"26","author":"NB Mercuri","year":"2005","unstructured":"Mercuri NB, Bernardi G. The \u201cmagic\u201d of L-dopa: why is it the gold standard Parkinson\u2019s disease therapy? Trends Pharmacol Sci. 2005;26(7):341\u20134.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1132_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11910-005-0072-6","volume":"5","author":"KR Chaudhuri","year":"2005","unstructured":"Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson\u2019s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep. 2005;5(4):275\u201383.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"1132_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/WCO.0000000000000118","volume":"27","author":"JC Giugni","year":"2014","unstructured":"Giugni JC, Okun MS. Treatment of advanced Parkinson\u2019s disease. Curr Opin Neurol. 2014;27(4):450\u201360.","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"1132_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl A, Kleinman L, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"1132_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung V, Lopiano L, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.","journal-title":"BMC Neurol."},{"issue":"3","key":"1132_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","volume":"22","author":"S Kalabina","year":"2019","unstructured":"Kalabina S, Belsey J, Pivonka D, et al. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales. J Med Econ. 2019;22(3):215\u201325.","journal-title":"J Med Econ."},{"issue":"5","key":"1132_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3111\/13696998.2011.598201","volume":"14","author":"J Lowin","year":"2011","unstructured":"Lowin J, Bergman A, Chaudhuri K, et al. A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK. J Med Econ. 2011;14(5):584\u201393.","journal-title":"J Med Econ."},{"issue":"11","key":"1132_CR22","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/13696998.2017.1379411","volume":"20","author":"J Lowin","year":"2017","unstructured":"Lowin J, Sail K, Baj R, et al. The cost-effectiveness of levodopa\/carbidopa intestinal gel compared to standard care in advanced Parkinson\u2019s disease. J Med Econ. 2017;20(11):1207\u201315.","journal-title":"J Med Econ."},{"issue":"2","key":"1132_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3111\/13696998.2014.979937","volume":"18","author":"E Walter","year":"2015","unstructured":"Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson\u2019s disease in the UK and Germany. J Med Econ. 2015;18(2):155\u201365.","journal-title":"J Med Econ"},{"issue":"3","key":"1132_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40266-013-0150-4","volume":"31","author":"JF Van Boven","year":"2014","unstructured":"Van Boven JF, Novak A, Driessen M, et al. Economic evaluation of ropinirole prolonged release for treatment of Parkinson\u2019s disease in the Netherlands. Drugs Aging. 2014;31(3):193\u2013201.","journal-title":"Drugs Aging."},{"issue":"1","key":"1132_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","volume":"261","author":"S Eggington","year":"2014","unstructured":"Eggington S, Valldeoriola F, Chaudhuri K, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease. J Neurol. 2014;261(1):106\u201316.","journal-title":"J Neurol."},{"issue":"7","key":"1132_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/ner.12474","volume":"19","author":"JB Pietzsch","year":"2016","unstructured":"Pietzsch JB, Garner AM, Marks WJ Jr. Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States. Neuromodulation. 2016;19(7):689\u201397.","journal-title":"Neuromodulation"},{"issue":"5","key":"1132_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"issue":"3","key":"1132_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","volume":"13","author":"PF Worth","year":"2013","unstructured":"Worth PF. When the going gets tough: how to select patients with Parkinson\u2019s disease for advanced therapies. Pract Neurol. 2013;13(3):140\u201352.","journal-title":"Pract Neurol"},{"key":"1132_CR29","unstructured":"Britannia Pharmaceuticals Ltd. APO-go PFS 5mg\/ml solution for infusion in pre-filled syringe, summary of product characteristics 2020. https:\/\/www.medicines.org.uk\/emc\/medicine\/15992#gref. Accessed 3 Feb 2022."},{"issue":"4","key":"1132_CR30","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3233\/JPD-202022","volume":"10","author":"V Leta","year":"2020","unstructured":"Leta V, van Wamelen D, Sauerbier A, et al. Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis. 2020;10(4):1535\u20139.","journal-title":"J Parkinsons Dis."},{"key":"1132_CR31","unstructured":"NHS. England announces annual investment decisions for certain specialised services 2015. 2015. https:\/\/www.england.nhs.uk\/2015\/07\/annual-investment- decisions\/. Accessed 3 Feb 2022."},{"key":"1132_CR32","unstructured":"NHS England. Clinical commissioning policy: levodopa-carbidopa intestinal gel (LCIG). D04\/P\/e DuoDopa for Parkinsons disease. 2015. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2015\/07\/d04-p-e.pdf. Accessed 3 Feb 2022."},{"issue":"2","key":"1132_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol."},{"issue":"6","key":"1132_CR34","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.27338","volume":"33","author":"HH Fernandez","year":"2018","unstructured":"Fernandez HH, Boyd J, Fung V, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. Mov Disord. 2018;33(6):928\u201336.","journal-title":"Mov Disord."},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri K, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13\u201320.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"1132_CR36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert D, Hauser R, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500\u20139.","journal-title":"Mov Disord."},{"issue":"3","key":"1132_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.parkreldis.2009.07.015","volume":"16","author":"V Puente","year":"2010","unstructured":"Puente V, Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson\u2019s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010;16(3):218\u201321.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"1132_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1600-0404.2011.01523.x","volume":"125","author":"D Santos-Garc\u00eda","year":"2012","unstructured":"Santos-Garc\u00eda D, Sanjurjo L, Macias M, et al. Long-term exposure to duodenal levodopa\/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand. 2012;125(3):187\u201391.","journal-title":"Acta Neurol Scand."},{"issue":"10","key":"1132_CR39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468\u201374.","journal-title":"Mov Disord."},{"key":"1132_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez H, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis. 2015;5:165\u201374.","journal-title":"J Parkinsons Dis."},{"issue":"8","key":"1132_CR41","doi-asserted-by":"publisher","first-page":"e00758","DOI":"10.1002\/brb3.758","volume":"7","author":"O De Fabregues","year":"2017","unstructured":"De Fabregues O, Dot J, Abu-Suboh M, et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav. 2017;7(8):e00758.","journal-title":"Brain Behav."},{"issue":"6","key":"1132_CR42","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, et al. The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther. 2021;38(6):2854\u201390.","journal-title":"Adv Ther."},{"issue":"3","key":"1132_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF03256150","volume":"7","author":"IS Kristiansen","year":"2009","unstructured":"Kristiansen IS, Bingefors K, Nyholm D, et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson\u2019s disease in Sweden. Appl Health Econ Health Policy. 2009;7(3):167\u201380.","journal-title":"Appl Health Econ Health Policy."},{"key":"1132_CR44","unstructured":"NICE Decision Support Unit. Technical support documents. http:\/\/nicedsu.org.uk\/technical-support-documents\/. Accessed 3 Feb 2022."},{"key":"1132_CR45","unstructured":"National Institute for Health and Care Excellence. PMG9: guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword. Accessed 15 Dec 2021."},{"issue":"3","key":"1132_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.25328","volume":"28","author":"SJ Johnson","year":"2013","unstructured":"Johnson SJ, Diener M, Kaltenboeck A, et al. An economic model of Parkinson\u2019s disease: implications for slowing progression in the United States. Mov Disord. 2013;28(3):319\u201326.","journal-title":"Mov Disord."},{"issue":"7","key":"1132_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1023\/A:1008903126315","volume":"9","author":"CS Palmer","year":"2000","unstructured":"Palmer CS, Schmier J, Snyder E, et al. Patient preferences and utilities for \u2018off-time\u2019 outcomes in the treatment of Parkinson\u2019s disease. Qual LIfe Res. 2000;9(7):819\u201327.","journal-title":"Qual LIfe Res."},{"issue":"9","key":"1132_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200220090-00005","volume":"20","author":"CS Palmer","year":"2002","unstructured":"Palmer CS, Nuijten M, Schmier J, et al. Cost effectiveness of treatment of Parkinson\u2019s disease with entacapone in the United States. Pharmacoeconomics. 2002;20(9):617\u201328.","journal-title":"Pharmacoeconomics."},{"key":"1132_CR49","unstructured":"Office for National Statistics. National life tables, UK: 2016 to 2018. 2019. https:\/\/www.ons.gov.uk\/releases\/nationallifetablesuk2016to2018. Accessed 20 Sept 2020."},{"key":"1132_CR50","unstructured":"AbbVie data on file. Adelphi Real-World Parkinson's Disease Specific Programme. 2019."},{"issue":"11","key":"1132_CR51","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes: a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin."},{"key":"1132_CR52","unstructured":"Monthly Index of Medical Specialities (MIMS). 2020; http:\/\/www.mims.co.uk\/. Accessed 3 Feb 2022."},{"key":"1132_CR53","unstructured":"NHS. NHS trusts and NHS foundation trusts. National schedule of reference costs: year 2017-2018. 2018. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 3 Feb 2022."},{"key":"1132_CR54","unstructured":"Curtis L, Burns A. Unit costs of health and social care 2018. Project report. Kent: University of Kent; 2018"},{"key":"1132_CR55","unstructured":"AbbVie data on file. Adelphi Real-World Parkinson's Disease Specific Programme. 2012."},{"issue":"11","key":"1132_CR56","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"key":"1132_CR57","unstructured":"AbbVie. Long-term study of duodopa (levodopa\/carbidopa) in advanced Parkinson's: health outcomes & net economic impact (DAPHNE). 2011. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00141518. Accessed 3 Feb 2022."},{"issue":"3","key":"1132_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"1132_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3111\/13696998.2010.551164","volume":"14","author":"LJ Findley","year":"2011","unstructured":"Findley LJ, Wood E, Lowin J, et al. The economic burden of advanced Parkinson\u2019s disease: an analysis of a UK patient dataset. J Med Econ. 2011;14(1):130\u20139.","journal-title":"J Med Econ."},{"issue":"1","key":"1132_CR60","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/13696998.2021.1913009","volume":"24","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E, et al. Real-world assessment of \u201cOFF\u201d episode-related healthcare resource utilization among patients with Parkinson\u2019s disease in the United States. J Med Econ. 2021;24(1):540\u20139.","journal-title":"J Med Econ."},{"issue":"3","key":"1132_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13696998.2019.1693383","volume":"23","author":"TM Shih","year":"2020","unstructured":"Shih TM, Sail K, Jalundhwala Y, et al. The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson\u2019s disease. J Med Econ. 2020;23(3):297\u2013307.","journal-title":"J Med Econ."},{"key":"1132_CR62","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.prdoa.2020.100046","volume":"3","author":"N Dahodwala","year":"2020","unstructured":"Dahodwala N, Pettit A, Jahnke J, et al. Use of a medication-based algorithm to identify advanced Parkinson\u2019s disease in administrative claims data: associations with claims-based indicators of disease severity. Clin Parkinsonism Relat Disord. 2020;3:100046.","journal-title":"Clin Parkinsonism Relat Disord."},{"issue":"12","key":"1132_CR63","first-page":"1529","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, et al. Advanced Parkinson\u2019s or \u201ccomplex phase\u201d Parkinson\u2019s disease? Re-evaluation is needed J Neural Transm (Vienna). 2017;124(12):1529\u201337.","journal-title":"Re-evaluation is needed J Neural Transm (Vienna)."},{"key":"1132_CR64","first-page":"7537924","volume":"2020","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus Fonticoba T, Castro E, et al. 5-2-1 Criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson\u2019s treatment. Parkinson Dis. 2020;2020:7537924.","journal-title":"Parkinson Dis."},{"key":"1132_CR65","unstructured":"Antonini APO, Odin P, Jalundhwala YJ, et al. Assessing the validity and reliability of MANAGE-PD tool to identify patients with Parkinson\u2019s disease inadequately controlled on oral medications: results from an international survey of general neurologists and movement disorder specialists [abstract]. Move Disord. 2019;34(Suppl. 2)."},{"issue":"5","key":"1132_CR66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/nmt-2020-0021","volume":"10","author":"J Aldred","year":"2020","unstructured":"Aldred J, Anca-Herschkovitsch M, Antonini A, et al. Application of the \u201c5-2-1\u201d screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag. 2020;10(5):309\u201323.","journal-title":"Neurodegener Dis Manag."},{"issue":"1","key":"1132_CR67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2191-1991-3-8","volume":"3","author":"T H\u00e4rk\u00e4nen","year":"2013","unstructured":"H\u00e4rk\u00e4nen T, Maljanen T, Lindfors O, et al. Confounding and missing data in cost-effectiveness analysis: comparing different methods. Health Econ Rev. 2013;3(1):8.","journal-title":"Health Econ Rev."},{"key":"1132_CR68","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01011-y","volume":"39","author":"C Kruse","year":"2021","unstructured":"Kruse C, Kretschmer S, Lipinski A, et al. Resource utilization of patients with Parkinson\u2019s Disease in the late stages of the disease in Germany: data from the CLaSP Study. Pharmacoeconomics. 2021;39:601\u201315.","journal-title":"Pharmacoeconomics."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01132-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T15:48:39Z","timestamp":1652284119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01132-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01132-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"23 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported and funded by AbbVie Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K. Ray Chaudhuri has received educational funding from UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, and Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic and Mundipharma. A. Simon Pickard is a partner in Second City Outcomes Research LLC and Maths in Health BV, and received funds as a paid consultant from AbbVie. Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Yanjun Bao, Julia Sus, and Christian Ridley are employees of AbbVie and may own stocks\/shares in the company. Glynn Jones was an employee of AbbVie at the time of the study. Julia Oddsdottir and Weiwei Xu are employees of IQVIA, which received funding to conduct the study. Seyavash Najle-Rahim and Matthew Madin-Warburton were employees of IQVIA at the time of the study. Anette Schrag was supported by research funding or support from University College London, National Institute of Health, National Institute for Health Research University College London Hospital Biomedical Research Centre, the International Parkinson and Movement Disorder Society, the European Commission, Parkinson's UK, GE Healthcare, and the Economic and Social Research Council; honoraria for consultancies from Biogen, AbbVie, Roche, BIAL and GE Healthcare; license fee payments from the University College London for the MSA-QoL, PSP-QoL and PQolCarers; and royalties from Oxford University Press.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that the data supporting the findings of this study are available within the article and\/or its supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Julia Oddsdottir and Prasanna L. Kandukuri. All authors commented on all drafts of the manuscript. All authors read and approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}